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Abstract
Purpose The aim of this study is to evaluate the toxicity of
holmium-166 poly(L-lactic acid) microspheres administered
into the hepatic artery in pigs.
Methods Healthy pigs (20–30 kg) were injected into the
hepatic artery with holmium-165-loaded microspheres
(
165HoMS; n=5) or with holmium-166-loaded micro-
spheres (
166HoMS; n=13). The microspheres’ biodistribu-
tion was assessed by single-photon emission computed
tomography and/or MRI. The animals were monitored
clinically, biochemically, and (
166HoMS group only) hema-
tologically over a period of 1 month (
165HoMS group) or
over 1 or 2 months (
166HoMS group). Finally, a pathological
examination was undertaken.
Results After microsphere administration, some animals
exhibited a slightly diminished level of consciousness and a
dip in appetite, both of which were transient. Four lethal
adverse events occurred in the
166HoMS group due either to
incorrect administration or comorbidity: inadvertent delivery
of microspheres into the gastric wall (n=2), preexisting
gastric ulceration (n=1), and endocarditis (n=1). AST levels
were transitorily elevated post-
166HoMS administration. In
the other blood parameters, no abnormalities were observed.
Nuclear scans were acquired from all animals from the
166HoMS group, and MRI scans were performed if available.
In pigs fromthe
166HoMS group, atrophy of one or more liver
lobes was frequently observed. The actual radioactivity dis-
tribution was assessed through ex vivo
166mHo measurements.
Conclusion It can be concluded that the toxicity profile of
HoMS is low. In pigs, hepatic arterial embolization with
166HoMS in amounts corresponding with liver-absorbed
doses of over 100 Gy, if correctly administered, is not
associated with clinically relevant side effects. This result
offers a good perspective for upcoming patient trials.
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Introduction
Internalradiationtherapywithyttrium-90(
90Y)-loaded micro-
spheres injected into the hepatic artery has demonstrated to
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Two
90Y microsphere products are currently commercially
available and in clinical use: TheraSphere® (MDS Nordion
Inc., Kanata, Ontario, Canada) and SIR-Spheres® (SIRTeX
Medical Ltd., Sydney, New South Wales, Australia). These
two devices differ considerably in physical characteristics,
particularly with regard to density and specific activity
(Table 1); TheraSphere® microspheres are glass micro-
spheres, consequently not biodegradable, and more impor-
tantly, of a high density compared to plasma [6]. This may
increase the risk of proximal intravascular settling [7]. SIR-
Spheres® are resin-based microspheres of near-plasma
density [8]. A disadvantage of SIR-Spheres® is the relatively
low specific activity [9], which necessitates the administra-
tion of relatively high amounts of these microspheres. This
has been reported to frequently lead to retrograde flow and/or
failure to deliver the intended dose [10, 11].
For tumor dosimetry calculations, quantitative imaging is
essential,whichwould also allow assessment oftheradiation
dose delivered to the non-tumorous liver tissue. As
90Yi sa
pure beta emitter, the only way to (quantitatively) assess the
biodistribution of the SIR-Spheres® and TheraSphere®
microspheres would be by means of Bremsstrahlung scans
of which the quality has unfortunately been demonstrated to
be insufficient for this purpose. At the nuclear medicine
department of the University Medical Center Utrecht
(Utrecht, The Netherlands), holmium-166 poly(L-lactic
acid) microspheres (
166HoMS) have been developed, which
have several advantageous properties when compared
with the available
90Y microspheres. The most important
advantage of the use of holmium is in imaging and
therefore also in dosimetry. Since
166Ho is a combined
beta-gamma emitter (Table 1), these microspheres allow for
quantitative nuclear imaging [12]; this allows that, instead
of using technetium-99m-labeled albumin macroaggregates
to predict the biodistribution of the microspheres [13]—
particularly in identification of excessive shunting to the
lungs, stomach, and/or duodenum—a small tracer dose of
166HoMS can be applied. Secondly, after administration of
the therapeutic dose, its distribution can be accurately
assessed. In addition, as holmium is a highly paramagnetic
element, it is suitable for (quantitative) MRI [14, 15],
especially useful for medium- and long-term monitoring of
the intrahepatic behavior of the holmium microspheres.
This property also allows for real-time visualization of the
deposition of microspheres during a (fully) MRI-guided
selective administration [16]. Other advantageous features
of holmium are its higher dose rate and its higher neutron-
absorption cross-section (Table 1), as a consequence of
which, considerably shorter reactor time is needed.
The pharmaceutical quality of the
166HoMS has been
extensively investigated and proven to be satisfactory [17–
19]. Furthermore, it must have been demonstrated, with aid
of adequate animal studies, that the device is expected to be
efficacious. Therefore, a non-survival biodistribution study
in rats was performed in which it was demonstrated that the
microsphere deposition was restricted to the tumor-bearing
liver lobe and that, in the tumorous tissue, the radioactivity
concentration was six times higher than in the non-target
liver tissue [20]. To definitely demonstrate that
166HoMS
injected into the hepatic artery have a tumoricidal effect, an
efficacy study in Vx2 carcinoma bearing rabbits was
performed [21]. In all animals treated with
166HoMS,
tumour growth was arrested and necrosis set in. Finally,
before initiation of a phase 1 clinical trial, it must be
ascertained that the toxicity profile of the device will be
acceptable. An extensive toxicity study in (non-tumor-
bearing) pigs has therefore been conducted. The porcine
model was chosen mainly for its body size, as a
catheterization procedure is involved in the treatment for
which the smaller laboratory animal species are unsuitable
[22]. The aim of this study was to investigate the acute and
medium-term toxicity of the
166HoMS and to ascertain
potential complications associated with the catheterization-
administration procedure.
Table 1 Microsphere
characteristics
aCalculated values
Microsphere TheraSphere® SIR-Spheres® Holmium
microspheres
Radionuclide Yttrium-90 Holmium-166
Radionuclide properties
T1/2 (h) 64.1 26.8
Maximum β
−-energy (MeV) 2.28 (99.9%) 1.77 (48.7%), 1.85 (50.0%)
γ-Energy (keV) No γ-emission 80.6 (6.7%)
Neutron cross-section (barn) 1.3 64
Matrix material Glass Resin Poly(L-lactic acid)
Density (g/ml) 3.3 1.6 1.4
Diameter (μm) 25±10 32±10 30±5
Activity/microsphere (Bq) 1,250
a−2,500 50
a 450
a
Number of microspheres per dose 4,000,000 50,000,000 33,000,000
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Study design
The study was divided into two substudies: The aim of the
first substudy, which consisted offive pig experiments, was to
evaluate the clinical effects of transcatheter hepatic arterial
administration of escalating amounts of (non-radioactive)
165HoMS (7.5–37.5 mg/kg in steps of 7.5 mg/kg); the second
substudy consisted of 13 pigs that were administered
166HoMS (200–300 mg) with the aim of assessing the
clinical effects of increasing amounts of radioactivity,
starting at 3.15 MBq
166Ho/g liver tissue. Escalation of
administered activity was implemented in increments of
3.15 MBq/g up to 9.45 MBq
166Ho/g liver tissue, corre-
sponding with an absorbed liver dose of 50, 100, and
150 Gy, respectively. Each group was intended to consist of
two to four animals, depending on the encountered side
effects. Animals in the
165HoMS group were sacrificed
1 month after microsphere administration and the animals in
the
166HoMS group randomized to termination 1 or 2 months
post-administration.
Animals
Eighteen healthy female pigs, 3–4 months old, weighing
20–30 kg, and specified pathogen-free, were obtained from
the Animal Sciences Group, Wageningen University and
Research Center, Lelystad, The Netherlands. A 2-week
acclimatization period was allowed. The animals were kept
under conventional conditions with ad libitum access to tap
water and given standard pelleted feed twice a day. The
experiments were conducted in agreement with the local
applicable Dutch law, “Wet op de dierproeven” (art. 9,
1977) and the European Convention for the Protection of
Vertebrate Animals used for Experimental and Other
Scientific Purposes (1986), and approved by the ethical
committee for animal experimentation of the University
Medical Center Utrecht, Utrecht, The Netherlands (DEC-
GNK no. 03.03.032).
Microsphere preparation
Good manufacturing practice (GMP) grade
165HoMS were
prepared as previously described [18, 23]. In the case of the
radioactive substudy, the microspheres were packed in
high-density polyethylene vials (Posthumus Plastics,
Beverwijk, The Netherlands) and neutron-activated via the
165Ho [n,γ]
166Ho reaction in the nuclear reactor of the
Delft University of Technology (Delft, The Netherlands)
with a thermal neutron flux of 5×10
12 cm
−2 s
−1 for a
predetermined length of time (1.5–7.5 h). After arrival at
the hospital, the microspheres were suspended in 1 ml of a
Pluronic® solution [24] and transferred into a glass V-
bottom vial. The amount of radioactivity was then
measured in a dose calibrator (VDC-404, Veenstra Instru-
menten B.V., Joure, The Netherlands).
Anesthesia and analgesia
Premedication for general anesthesia consisted of azaperon
(4 mg/kg), ketamine hydrochloride (10 mg/kg), and atropine
(0.1 mg/10 kg) IM. Induction of general anesthesia consisted
of thiopental (5–10 mg/kg) or propofol (2.5–3.5 mg/kg) IV.
General anesthesiawasmaintainedbycontinuousintravenous
infusion of 8–9 mg/kg per hour propofol or by inhalation of
isoflurane (1.5–2.0%) in O2/air (1:1) in combination with
midazolam hydrochloride (0.2 mg/kg) IV. Perioperative
analgesia was provided by sufentanil (loading dose, 5 μg/kg;
maintenance dose, 10 μg/kg per hour) IV. Perioperative
antibiotic prophylaxis consisted of a preoperative dose of
amoxicillin with clavulanic acid (10 mg/kg) IV.
Postoperative medication consisted of buprenorphine
(0.015 mg/kg) and carprofen (4 mg/kg) IV, and ampicillin
(7.5 mg/kg) IM. The animals were terminated by an
overdose of sodium pentobarbitone (100–200 mg/kg) IV
after ketamine sedation.
Chronic intravascular catheter
For convenient withdrawal of blood samples and adminis-
tration of medication, a 7F silicone catheter (Instech
Solomon, Plymouth Meeting, PA, USA) was inserted into
the external jugular vein and immobilized and then subcu-
taneouslytunneledtoexitdorsally between thescapulas.The
postoperative protocol consisted of dailyflushing with saline
andinjectionofaheparinsalinesolution intothecatheter and
topical antibacterial prophylaxis (procaine benzylpenicillin
200,000 IE/ml + dihydrostreptomycin 200 mg/ml) on the
exit site for 2 weeks.
Catheterization and microsphere administration
An Avanti®+ catheter sheath introducer (5F, Cordis Europe
N.V., Roden, The Netherlands) was inserted into the right
femoral artery. The catheters deployed in the experiments
were Performa® Modified Hook Flush, Softouch® Osborn
2 and Softouch® Straight Flush, in combination with
double-ended (J-tip and straight tip) and straight fixed core
(super stiff) guide wires (Merit Medical Europe, Maastricht-
Airport, The Netherlands). The tip of the catheter was
positioned in A. hepatica propria, i.e., in the hepatic artery,
distally to where the gastroduodenal artery branches off.
The microspheres were flushed out of the vial and into the
catheter by injecting 15–20 ml of saline solution into the
vial at a rate of 0.5–1.0 ml s
−1.
Eur J Nucl Med Mol Imaging (2008) 35:1259–1271 1261Imaging protocols
Microsphere distribution was assessed by single photon
emission computed tomography (SPECT), planar nuclear
imaging, and (if available) MRI, 3 days post-administration.
Immobilization was obtained by propofol, after premedica-
tionwithketamine.TheSPECTandMRIscanswereacquired
according to previously described protocols [12, 14].
Dosimetry
The absorbed liver doses were calculated as follows. For
166Ho, the calculated absorbed energy is 15.87 mJ MBq
−1,
based on S values, as calculated by Dr. M. W. Konijnenberg
(Mallinckrodt Inc., Tyco Healthcare, Petten, The Netherlands)
through the use of the Monte-Carlo MCNPX code (Los
Alamos National Laboratory, Los Alamos, New Mexico,
USA). Assuming that all energy is absorbed in the liver, the
cumulative dose (mGy MBq
−1) may be calculated to be
15.87 mJ MBq
−1/liver weight (kg). The weight of the porcine
liver equates to 1.97% of the body weight [25]. Thus, for
example, in a pig of 25 kg with a liver of approximately
490 g in which 4,500 MBq
166Ho is administered, the
absorbed organ dose is 15.87×10
−3 JM B q
−1 ×4 , 5 0 0M B q /
0.490 kg=146 Gy.
Clinical follow-up
The animals weremonitoredfor clinical sideeffects ona daily
basis. Clinical parameters monitored included demeanor,
consciousness level/alertness, posture and gait, food intake,
and growth (the animals were weighed twice a week).
Blood samples were taken before microsphere administra-
tion (baseline values), 10 min after delivery of the micro-
spheres, and twice a week until termination. Hemoglobin
(Hb), leukocyte count, and platelet count were determined
within 4 h of sampling using a Cell-Dyn® 4000 hematology
analyzer (Abbott Laboratories, Santa Clara, CA, USA).
Prothrombintime(PT)wasdeterminedwithin4hofsampling
using a STA® coagulation analyzer (Diagnostica Stago,
Asnières, France). Plasma samples for chemical analyses
werestoredafter centrifugationandkeptfrozenat−20°Cuntil
analysis. Gamma-glutamyltransferase (GGT), alkaline phos-
phatase (ALP), alanine aminotransferase (ALT), aspartate
aminotransferase (AST), and bilirubin were analyzed, using a
Vitros® 950 chemistry system (Ortho Clinical Diagnostics,
Rochester, NY, USA).
Postmortem examination
After termination, a gross pathological examination was
performed, during which the liver and gallbladder, spleen,
lungs, and stomach were collected and processed for
histological examination. Tissue sections (4-μm thick) were
routinely prepared and stained with hematoxylin and eosin
and evaluated by light microscopy.
Ex vivo radioactivity distribution assessment
The liver and gallbladder, spleen, lungs, and stomach of the
animals, which had been administered with
166HoMS, were
processed into a homogeneous suspension using a kitchen
blender and chemical destruction (sodium hydroxide
8.25 mmol/l). For every organ suspension, the content of
holmium-166 metastable (
166mHo, T1/2≈1,200 years) was
measured directly using a low-background gamma-counter
(Tobor, Nuclear Chicago, Chicago, IL, USA). During
neutron activation, both
166Ho and
166mHo are formed
(
166Ho/
166mHo≈1,000,000:1). Since the
166mHo interorgan
distribution is linear to the
166Ho distribution, the interorgan
radioactivity distribution of the
166HoMS could then be
calculated accurately.
Results
Clinical follow-up
In the non-radioactive experiments, the amount of
165HoMS was escalated up to 700 mg, which on a
bodyweight basis, corresponds to three times the amount
that will be administered to patients. Whether the entire
dosage was selectively deposited in the liver and whether or
not a significant part of the injected microspheres had
ended up in organs other than the liver could not be
quantitatively assessed. In the radioactive experiments,
between 1.4 and 6.5 GBq
166Ho was administered, which
(when corrected for extrahepatic deposition) equates to
attained whole-liver nominal absorbed doses of between 59
and 162 Gy; Table 2 gives an overview of the amounts of
microspheres actually administered and, where appropriate,
the real amounts of radioactivity that were delivered and,
accordingly, the estimated absorbed liver doses.
After the catheterization-administration procedure,
inappetence and a slightly diminished state of conscious-
ness, both of which were transient, were observed in some
animals in both substudies. Typically, in a couple of days,
consciousness level and appetite returned to pretreatment
levels. However, daily contact (for at least 20 min) between
researcher and pig beginning 2 weeks before the start of the
experiment clearly advanced the return of appetite within
2 days for most of the animals.
In total, five serious adverse events were observed
(Table 3). Complications that occurred were either due to
erroneous microsphere delivery, i.e., extrahepatic deposi-
tion, or due to comorbidity, with the exception of pig 3.
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165HoMS and experienced a
paraparesis, probably attributable to a catheterization-
related cord infarction that spontaneously resolved within
24 h. In pigs 8 and 10, treated with radioactive micro-
spheres, clinically significant backflow into the gastroduo-
denal artery occurred. This artery conveys blood to the
stomach, duodenum, and the pancreas and arises from the
common hepatic artery, close to the origin of the right and
left hepatic artery (Fig. 1a,b) [26]. Pig 8 expired from
multifocal perforating gastric ulceration and peritonitis
6 days post-administration, and pig 10 was euthanized
when excessive deposition of radioactivity in the stomach
was observed on the nuclear scans. Pig 12 was diagnosed
with severe persistent anemia (Hb<2.5 mmol/l) 1 week
post-operation and died from heart failure on day 20.
During postmortem examination, the animal was found to
have suffered from multiple perforating gastric ulcers,
which were not confined to the esophageal region. A
Table 3 Adverse events
Pig no. Adverse event Comment Clinical outcome
3 Transient paraparesis Ascribed to a spinal cord infarction Resolved within 24 h
8 Acute peritonitis, necrosis of the stomach wall
and full-thickness gastric wall rupture
Due to inadvertent administration of
166HoMS into
A. gastroduodenalis
Found dead at day 6
10 Multifocal ulceration of the stomach,
one large perforating ulcer
As a consequence of backflow of
166HoMS into
A. gastroduodenalis
Euthanized at day 5
12 Chronic anemia due to persistently bleeding
ulcer
Pepsinogen serum levels revealed that the peptic ulcer
was present before
166HoMS had been administered
Demise from heart failure
at day 20
15 Endocarditis of the tricuspid valve, chronic
anemia due to persistently bleeding ulcer
The endocarditis was most probably associated with
unhygienic blood withdrawal from the chronic
intravascular catheter
Euthanized at day 53
Table 2 Overview of the pig experiments
Pig no. Body weight
(kg)
a
Administered dosage of HoMS Absorbed liver
dose (Gy)
e
Imaging
modalities
Termination time
(days post-administration)
mg
b MBq Specific activity
(MBq/mg)
c
MBq/g liver
d MRI SPECT
1 21.8 159 −− − − − − 30
2 18.0 320 −− − − − − 30
3 18.7 430 −− − − − − 30
4 18.0 599 −− − − − − 30
5 19.4 700 −− − − + − 30
6 21.9 294 1,786 6.1 4.1 66 (50) + + 30
7 19.0 240 2,439 10.2 6.5 103 (100) + + 60
8 18.2 281 4,409 15.7 6.3 101 (150) − +6
9 19.3 221 1,410 6.4 3.7 59 (50) + + 60
10 20.0 244 3,133 12.8 3.8 60 (100) + + 5
11 20.1 297 2,657 8.9 6.7 107 (100) + + 60
12 19.1 278 2,846 10.2 7.6 120 (150) − +2 0
13 24.5 157 2,954 18.8 6.1 97 (150) + + 60
14 26.4 138 3,371 24.4 6.5 103 (150) + + 30
15 29.7 170 5,825 34.3 8.3 132 (150) + + 53
16 28.8 191 5,874 30.8 6.7 106 (150) + + 30
17 28.2 192 6,485 33.8 10.2 162 (150) − +3 0
18 29.3 223 5,895 26.4 7.4 118 (150) − +6 0
aBody weight at time of administration.
bRegarding the administered amount of microspheres in the non-radioactive experiments (pig no. 1–5) it was assumed that the entire administered
dose was selectively deposited in the liver.
cIn the last six experiments specific activity was higher (hence number of microspheres lower) to reduce the risk of backflow.
dAccording to literature (Boxenbaum et al., 1979) the weight of the porcine liver equates to 1.97% of its body weight. The portion of the
administered amount of radioactivity actually delivered into the liver was calculated by measuring the
166mHo contents in the ex vivo organs.
eThe organ dose was calculated as follows: [15.87 mJ ∙ MBq
-1 ∙ A (MBq)/LW (kg)] × 10
–3 (where A is administered amount of radioactivity and
LW is liver weight). Intended liver dose is given between parentheses.
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animal underwent
166HoMS administration, as was demon-
s t r a t e db yt h e( d i f f e r e n c ei np r e -a n dp o s t - t r e a t m e n t )
pepsinogen serum levels (data not shown). Pig 15 had to
be euthanized prematurely because of its poor clinical
condition; 7 weeks after
166HoMS administration, it was
found in a lethargic state, feverish, and unwilling to eat. It
was also very anemic (Hb<3.0 mmol/l) and exhibited signs
of consumption coagulopathy. Despite antibacterial and
antipyretic treatment, and supportive care, its condition
continued to deteriorate and required euthanization at
day 53. At necropsy, an endocarditis, most probably
infective, was found, almost certainly associated with
unhygienic blood withdrawal from the chronic intravascular
catheter. Deep gastric ulcers were also found, the largest
one being in the pars oesophagea of the stomach.
Laboratory evaluation
Hematological and (especially) hematochemical reference
values of healthy pigs vary considerably between sources
[27–29]. This is because different analysis methods had
been used and because the measured values of some
parameters are highly age-dependent (e.g., ALP, of which
the serum levels are higher in growing animals). Most
blood reference values from literature could therefore not
be used in this study. Instead, it was decided to compare the
mean values of the samples obtained post-treatment with
the mean of the baseline values for each parameter.
The serum activities of GGT, ALP, and ALT exhibited
no clinically relevant changes (Fig. 2a–c). In the ALP
serum levels, a trivial difference was observed between the
165HoMS group and the
166HoMS group, which was already
present in the baseline values. After radioactive microsphere
administration, a moderate and transient elevation of AST
levels was observed (Fig. 2d). In most samples, bilirubin
was not detectable, and in the few in which it was
detectable, levels did not surpass 4.0 μmol/l (data not
shown). Mean hemoglobin levels were all higher than the
mean of the hemoglobin baseline levels (Fig. 3a), even
though the two animals diagnosed with severe persistent
anemia were also included in the analysis. Similarly, platelet
counts in the initial post-procedural samples were low,
compared to those in samples collected later (Fig. 3b). The
platelet counts varied considerably, both intra- and inter-
individually, but remained in the normal range. The mean
total leukocyte count also remained within normal limits
(Fig. 3c) [27]. Prothrombin time was not prolonged in any
of the samples (Fig. 3d).
Postmortem examinations
The main pathological findings of the animals are summa-
rized in Table 4. In the pigs that had been administered non-
radioactive holmium microspheres, no gross abnormalities
wereseen, except for the liver ofpig 3 (22.5 mg
165HoMS/kg)
in which the right lobes showed moderate atrophy and the
left lobes slight (compensatory) hypertrophy. In one animal
in this group, ulceration of the esophageal region of the
stomach was seen. Moderate to marked atrophy of one or
more liver lobes with compensatory hyperplasia of the other
lobes was frequently observed in the animals treated with
radioactive holmium microspheres (Table 4). In five animals
(all from the
166HoMS substudy), moderate to extensive,
often perforating, ulceration of the cardiac, fundic, and/or
antral regions of the stomach was observed. In five animals,
ulceration of the esophageal region of the stomach was seen
(Table 4). In two animals, infarction of the gallbladder was
observed (Table 4).
Histological examinations of the pigs of the
165HoMS
group regularly showed small and sometimes larger aggre-
gates of microspheres in arteries of the liver, as well as some
solitary intra-arteriolar microspheres in the stomach and
gallbladder. Larger aggregates in the livers were associated
Fig. 1 MR arteriography of the
thorax and abdomen of a pig,
anteroposterior projection
(a); excerpt of a (b): common
hepatic artery (1), splenic artery
(2), caudal phrenic artery (3),
gastroduodenal artery (4),
(branches of the) proper hepatic
artery (5), right hepatic artery
(6), medial hepatic arteries (7),
left hepatic artery (8), and right
gastric artery (9)
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surrounding individual spheres (Fig. 4a). In pig 3, in the
right lateral liver lobe, a large portal area was seen with
coagulative necrosis, surrounded by multinucleated giant
cells, many pigmented macrophages and a fibrous capsule.
In this capsule, some large aggregates of spheres were
present (Fig. 4b). In the surrounding atrophic parenchyma,
moderately broadened interlobular septa with fibrosis and
arteriolar and ductular proliferation were seen; within these
septa, small aggregates of microspheres were present.
Histological examinations of pigs 8 and 10 in the
166HoMS
group, which died spontaneously at day 6 and was
euthanized in extremis at day 5, respectively, showed
multifocal aggregates in the hepatic arteries in the portal
tracts. These aggregates were associated with complete
necrosis of the portal area and the adjacent parenchyma
(Fig. 4c). In the stomach of these animals, intra-arteriolar
aggregates were sometimes seen, associated with thrombosis
and necrosis of the arteriolar wall (Fig. 4d). In the other pigs
in this group, which survived for 30 or 60 days, in the
atrophic liver lobes, large aggregates of microspheres were
frequently seen, associated with large areas of coagulative
necrosis (often with yellow discoloration by bile imbibition)
and surrounded by multinucleated giant cells, pigmented
macrophages, and a fibrous capsule (Fig. 4e). In the two
animals with infarction of the gallbladder, there was necrosis
of the wall of the gallbladder with fibrous encapsulation. In
the lumen of the gallbladder necrotic debris, inspissated bile
and bile containing macrophages were present. An intra-
arteriolar aggregate was sometimes observed within the
fibrous capsule (Fig. 4f). Histological examinations of the
spleen in both groups showed only very rarely a solitary
microsphere without additional histological changes. In none
of the animals were microspheres seen in the lungs.
Imaging and microsphere biodistribution
Nuclear scans (planar and SPECT) were acquired in all 13
radioactive experiments. The distribution of radioactivity
was assessed by ex vivo
166mHo measurements. Figure 5a
shows a planar nuclear scan in which highly selective
hepatic accumulation of the radioactivity is demonstrated,
as was the case in seven animals in which, according to the
166mHo measurements, more than 95% of the injected dose
was deposited in the liver. On the scans of six animals,
accumulation of
166HoMS in the stomach was observed;
although clinically inconsequential, on the scans of four
pigs, a low to moderate amount of radioactivity (<20%)
was shown to be present in the stomach (Fig. 5b). In two
other animals (pigs 8 and 10), the scans revealed excessive
Fig. 2 Liver enzymes serum activities. Time in between samples was 3 or 4 days, and value 1 was derived from samples taken before
microsphere administration: serum activities of GGT (a), serum activities of ALP (b), serum activities of ALT (c), serum activities of AST (d)
Eur J Nucl Med Mol Imaging (2008) 35:1259–1271 1265deposition of radioactivity in the gastric wall (48% and
53% of injected activity, respectively; Fig. 5c). In none of
the experiments was
166Ho detected to be present in the
lungs. This was in accordance with the histological
examinations. In two animals, a portion of the radioactivity
was delivered to the spleen (~10%). The nuclear scans
revealed that the intrahepatic microsphere distribution was
distinctly heterogeneous.
MRI scans were obtained in one non-radioactive
experiment (pig 5) and in nine radioactive experiments
(Table 2; Fig. 6a–f). While the intrahepatic distribution of
the microspheres could be accurately assessed, demonstra-
tion of either presence or absence of microspheres in the
lungs proved to be unfeasible, as the holmium-based
artifacts on T2*-weighted images are black, as is the air in
the lungs. The presence of stomach gas and other contents
also made it very difficult to assess whether microspheres
had been deposited into the gastric wall.
Discussion
The clinical effects of (non-radioactive)
165Ho and (radio-
active)
166Ho poly(L-lactic acid) microspheres when
injected into the proper hepatic artery using a catheter were
investigated in non-tumor-bearing pigs. With regard to the
165HoMS, it was investigated whether the administration of
increasing amounts of microspheres would lead to signs of
toxicity. The aim of the
166HoMS substudy was to evaluate
the effects of escalating absorbed liver doses (from 50 up to
150 Gy). All animals were extensively monitored, both
clinically, hematologically, and biochemically. After termi-
nation, a postmortem examination was undertaken. As
quantitative
166Ho SPECT for clinical application is still in
development, (the extent of) extrahepatic microsphere
deposition was quantified through measuring the relative
166mHo content in organ homogenates.
Gastric ulcers have been a frequently encountered
pathological finding in this study, located both in the
esophageal region and in other parts of the stomach.
Although gastric ulceration in the esophageal region is a
very common abnormality in pigs and considered a mainly
husbandry-related phenomenon [30], it nonetheless can
have a fatal outcome (due to persistent hemorrhage). One
animal in this study (pig 12) died as a consequence of very
severe persistent gastric bleeding, and although the gastric
ulcers found at gross pathological examination were not
confined to the esophageal region, a bleeding ulcer was
most probably already present when the animal underwent
166HoMS administration, as was demonstrated by the
Fig. 3 Hematological values. Time in between samples was 3 or 4 days, and value 1 was derived from samples taken before microsphere
administration: hemoglobin concentrations (a), platelet counts (b), leukocyte counts (c), prothrombin time (d)
1266 Eur J Nucl Med Mol Imaging (2008) 35:1259–1271(difference in pre- and post-treatment) pepsinogen serum
levels [31, 32]. After this event, the animals to be used in
all remaining experiments were transported from the
supplier under mild sedation with azaperon to help reduce
stress and given antacid medication (sucralfate suspension).
The pigs were visited by the researcher on a daily basis,
starting in the acclimatization period, both to help them get
acquainted with the researcher and to provide a diversion
from daily routine. Pig 15 also developed a severe anemia
due to bleeding ulcers, but because the onset was more than
6 weeks post-treatment, it was certainly not related to the
microsphere treatment. As this animal also suffered from a
Fig. 4 a Liver of pig 3 (
165HoMS): aggregate of microspheres within
a hepatic artery with fibrosis and multinucleated giant cells. b Liver of
pig 3 (
165HoMS): large portal area with necrosis surrounded by
macrophages and multinucleated giant cells and a fibrous capsule with
large aggregates of microspheres. c Liver of pig 8 (
166HoMS): a
confined moderate-sized aggregate, probably within a hepatic artery,
surrounded by hepatic necrosis and hemorrhage of the surrounding
parenchyma and partial necrosis of the portal structures. d Stomach of
pig 10 (
166HoMS): submucosal artery with microspheres associated
with fibrinoid deposition and necrosis of the arterial wall. e Liver of
pig 11 (
166HoMS): large area with yellow necrosis and a large
aggregate of microspheres within a necrotic hepatic artery. f Gall-
bladder of pig 16 (
166HoMS): lumen filled with necrotic debris,
macrophages, and some neutrophils. Marked fibrosis of the wall with
an aggregate of microspheres within an artery
Table 4 Main pathological
findings
HR hilar region, LM left medial
lobe, LL left lateral lobe, RL
right lateral lobe, RM right
medial lobe
Pig no. Liver atrophy Liver necrosis Gallbladder
infarction
Gastric ulcers
Antrum, corpus
and/or fundus
Esophageal
region
1 −− − − +
2 −− − − −
3 + (RL, RM) + (RL) −− −
4 −− − − −
5 −− − − −
6 −− − − −
7 −− − − −
8 − + (RL) − + −
9 + (RL) −− − −
10 − + (RM) − + −
11 + (RM, LM) + (RM) −− −
12 + (LL, LM) + (RL, RM, LM, LL) − ++
13 + (LL, LM) −− − −
14 − + (HR, RL, LM) + −−
15 + (LM, LL) + (RL, LM, LL) − ++
16 + (RL, RM) + (RM) + − +
17 + (LM, LL) + (LM, LL) − + −
18 + (RM, LM, LL) + (RL, RM) −− +
Eur J Nucl Med Mol Imaging (2008) 35:1259–1271 1267septic endocarditis, which will have brought about distress
and anorexia, it is more likely that the ulcers, hence the
persistent blood loss, were associated with this comorbidity.
During the course of the experiments, the use of chronic
intravascular catheters has proved to be ideal, both for the
administration of intravenous medication and for obtaining
blood samples. However, it must be stressed that, to minimize
the risk of catheter-related infections or even sepsis, these
devices should be operated in a strictly sterile manner.
The key component of a toxicity study is usually the
pharmaceutical compound that is administered to the animal.
In this radioembolization study, as well as the pharmaceu-
tical quality of the microspheres, a very important factor was
the manner in which the catheterization-microsphere admin-
istration procedure was carried out. The most important
(lethal) complication that has occurred was inadvertent
deposition of an excessive amount of
166HoMS in the
gastric wall (pigs 8 and 10), as a consequence of which
perforating ulcers were induced. The cause of this radio-
embolization of the stomach was most probably uninten-
tional injection of microspheres into the gastroduodenal
artery, as a result of inaccurate catheter positioning, and/or
too high a force applied to flush the microspheres into the
proper hepatic artery, thus resulting in retrograde flow.
Catheter manipulation can also lead to vasospasm, for
which pigs are predisposed, further increasing the risk of
backflow. In the last six experiments, the specific activity of
the
166HoMS was increased (from ~10 to ~25 MBq/mg);
hence, the amount of microspheres to be administered
significantly decreased (Table 2). Until these experiments, a
hockey-stick-shaped catheter was used, both to pass the
celiac axis and to administer the microspheres. To reduce the
risk of backflow, in the subsequent experiments, the micro-
spheres were administered using a straight-tip catheter.
Fig. 6 In vivo coronal (a–c)a n d
transverse (d–f)M Ri m a g e so f
pig 17. The anatomical
images are found in a and
d (T1-weighted SE), and b and
e (T2-weighted SE images).
c and f The holmium-sensitive
T2*-weighted GE images. In the
T1-weighted SE images, the
vessels and gallbladder show up
as hypo-intense structures and as
hyperintense structures in the
T2-weighted SE images. In the
T2*-weighted GE images,
the clusters of microspheres are
visualized as additional focal
regions of signal loss, especially
in the dorsal region
Fig. 5 Nuclear images of pigs administered
166HoMS. Planar nuclear
scan of pig 15, demonstrating highly selective deposition of
166HoMS
microspheres in the liver (a); planar nuclear scan of pig 18, on which a
substantial amount of
166Ho (17.4%) is revealed to be present in the
gastric wall (b); planar nuclear scan of pig 10, demonstrating
excessive amounts of radioactivity (52.5% of injected dose) present
in the stomach. An intense hotspot in the lesser curvature of the
stomach is depicted by the arrow (c)
1268 Eur J Nucl Med Mol Imaging (2008) 35:1259–1271Furthermore, in the last eight experiments, an iodine contrast
agent (Telebrix® 35) was added to the flushing fluid (50:50)
to be able to monitor for backflow using X-ray C-arm
imaging. In the remaining experiments, deposition of
excessive amounts of
166HoMS into the gastric wall did
not occur, although, in four cases, there was still some
radioactivity (<20% of injected dose) present in the
stomach wall. Backflow into A. gastroduodenalis still
cannot be fully excluded, but it is more likely that a portion
of the microspheres ended up in the A. gastrica dextra
(Fig. 1), which branches off the hepatic artery distally from
the site of the catheter tip positioning during administration.
It has been reported in the literature (on human patients)
that both A. gastroduodenalis and A. gastrica dextra are
able to be prophylactically occluded, usually by coiling [33,
34]. As the aim was for the whole liver to be exposed to the
treatment, superselective microsphere administration was
not performed.
As the focus of this study was not on imaging but on
potential toxic side effects of these microspheres and because
quantitativeSPECTanalysis will only be availableinthenear
future, this was refrained from and the SPECT scans merely
analyzed in a semi-quantitative fashion. It was opted instead
to quantify the actual biodistribution by measuring the
166mHo content in the ex vivo organs. The nuclear imaging
did prove very useful for the detection of radioactivity
deposition into the lungs. As mentioned earlier, MRI could
not exclude holmium microsphere presence in the lungs or
(hardly) in the stomach wall. However, it could be used to
detect shunting to the lungs by measuring the holmium
content in blood passing through the Vena cava caudalis, as
was proposed in a previous paper [15].
In this study, it was demonstrated that pigs can cope with
extremely high liver absorbed doses, up to over 100 Gy in
nine experiments. The maximum organ dose to the (human)
liver from external beam radiation is approximately 30–
35 Gy [35, 36] or well below the range where tumoricidal
effects can be expected. Apart from biological effective
dose considerations like differences in dose rate, one
explanation for this phenomenon is the distinctly inho-
mogeneous intrahepatic distribution of radioactivity, as was
visualized by the nuclear and MRI scans.
Despite the overall lack of clinical signs in the pigs or,
more specifically, symptoms of liver disease, postmortem
examinations did reveal abnormalities in most of the
animals. The extent and severity of the abnormalities
differed considerablybetween the two groups. In the animals
which had beeninjected with
165HoMS, only very mild liver
changes were observed, whereas the livers that had been
exposed to
166HoMS showed blatant changes, i.e., gross
atrophy (accompanied with compensatory hypertrophy) and
(microscopic) coagulative necrosis of parts of the livers. In
itself, this is what can be expected after embolization of the
hepatic artery with microspheres loaded with high amounts
of a high-energy beta-emitting radionuclide.
In the monitored hematological parameters, no alter-
ations were seen (except in the animals that suffered from
persistently bleeding ulcers). The absence of myelosup-
pression was as expected because, in previously conducted
in vitro and in vivo studies, it was demonstrated that only a
very small fraction of the holmium-166 is released from the
microspheres [37–39]. Overall, hematochemical abnormal-
ities were absent, with the exception of the AST levels in
the
166Ho group; a transient rise in which these levels
roughly doubled from samples 2 to 3 (Fig. 2d) was seen,
which is in accordance with the postmortem findings,
specifically the presence of ischemic/necrotic tissue for
which AST is an indicator in the pig [40], and this accords
also with the literature on
90Y microsphere treatment, in
which a transient rise in the liver enzymes serum levels is
usually reported [34, 41].
After chemoembolization, the incidence of the so-called
post-embolization syndrome, which includes fatigue,
nausea, emesis, and/or right upper quadrant pain, is very
high [42, 43]. These symptoms have been reported after
90Y microsphere infusion as well but the incidence is low
[2, 44]. Therefore, as expected, in this pig study, no
vomiting was seen as well even if appetite was usually
temporarily decreased. The animals exhibited no signs of
abdominal pain.
Despite the fact that the cystic artery, which conveys
blood to the gallbladder, branches off the right medial
hepatic artery distally, similarly to A. gastrica dextra,
gallbladder pathology was observed in only two animals.
It can be postulated that the reason for the absence of
pathological findings in the gallbladders of the other pigs is
that premedication consisted of atropine, which blocks
parasympathetic activity, resulting in a decreased blood
flow in this feeble artery during the microsphere adminis-
tration. Gallbladder pathology (radiation cholecystitis)
subsequent to
90Y microsphere treatment is a frequently
described complication in the literature [9, 45]. Never-
theless, in most centers, a cholecystectomy preceding
90Y
microsphere therapy is not standard procedure.
Before patients undergo treatment with
90Ym i c r o -
spheres, a nuclear scan is acquired after hepatic arterial
injection with technetium-99m-labeled macroaggregates.
One of the reasons for this is to monitor for and/or quantify
hepatopulmonary shunting, as excessive delivery of micro-
spheres into the lungs can obviously lead to pulmonary
failure. Whereas in (primary) liver cancer patients, all kinds
of anomalous arteriovenous connections commonly exist
[34], this is not usually the case in healthy humans or in
healthy pigs. Therefore, as could be expected, no radioac-
tivity was detected in the lungs in any of the experiments,
neither on any of the scans nor on histological slides.
Eur J Nucl Med Mol Imaging (2008) 35:1259–1271 1269In this study, the critical factor has been demonstrated to
be the administration technique. In summary, the catheter
should be positioned correctly, i.e., the tip distally from
where A. gastroduodenalis branches off the common
hepatic artery, and the flushing force/rate kept low. In
addition, the specific activity of the microspheres should be
sufficiently high, and backflow should be monitored or
altogether inhibited by coiling.
It can be concluded that the toxicity profile of the
holmium poly(L-lactic acid) microspheres is low. If the
microspheres were administered in a correct manner, viz.
deposited selectively into the liver, hepatic arterial embo-
lization in pigs, with
166HoMS in high doses, was well
tolerated and the clinical side effects notably mild. Owing
to the favorable outcome of this animal study, phase 1
clinical trials are being planned for the near future.
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